Home > Selected Past Studies
SELECTED PAST STUDIES - All Cancers - Lung Cancer
Study
Disease
type & number of samples
Specific Requirements
associated data required
LC-1
Non-Small Cell Lung Carcinoma
FFPE Blocks
Retrospective
More than 3500 subjects
- 6 FFPE sections for screening of a specific mutation
- The corresponding FFPE blocks should remain available until the selection of positive blocks is completed
- Demographic, diagnostic and medical data
- Stage (TNM, grade)
LC-2
Non-Small Cell Lung Carcinoma & Squamous Cell Lung Carcinoma
Tissue Microarrays (TMA)
Prospective
More than 1000 subjects
4 groups:
- 50% Squamous cell Lung Carcinoma
- 4 groups (one group per stage)
- 50% Primary Lung Adenocarcinoma
- 4 groups (one group per stage)
- SCLC and NSCLC primo diagnosis
- No Asian subjects
- Also 5 FFPE slices placed in Eppendorf tube and one stained slide defining the punched area
- Demographic, diagnostic and medical data
- Stage (TNM, grade), % tumor cells in sample
- Smoking status
- Clinical history including Disease-free survival, Overall survival
- IHC results
LC-3
Non-Small Cell Lung Cancer (ALK)
FFPE Blocks
Retrospective
More than 150 subjects
- NSCLC with positive Anaplastic Lymphoma Kinase (ALK+) rearrangements
- Several biobanks can participate with a minimum of 10 cases/biobank
- Demographic, diagnostic and medical data
- Stage (TNM, grade)
- Method used for determination of ALK positivity
LC-4
Non-Small Cell Lung Cancer (PD-L1)
Plasma
Prospective
More than 30 subjects
- Positive for FFPE PD-L1 expression assessed by ICH
- Demographic, diagnostic and medical data
- Stage (TNM, grade)
LC-5
Non-Small Cell Lung Cancer (PD-L1)
FFPE Blocks
Retrospective
More than 30 subjects
- PD-L1 expression assessed by ICH
- Demographic, diagnostic and medical data
- Stage (TNM, grade)
LC-6
Non-Small Cell Lung Cancer (ALK)
Whole Blood and Matched FFPE Blocks
Prospective
More than 40 subjects
- 20ml of whole blood
- The tissue and blood collection must have been done with a maximum of 1 month from each other
- Whole blood collected in 2 different types of tubes and shipped at room temperature
- Demographic, diagnostic and medical data
- Stage (TNM, grade)
- Treatment History
LC-7
Non-Small Cell Lung Cancer (EGFR)
FFPE Blocks
Prospective
More than 40 subjects
- Locally advanced or metastatic NSCLC – stage IIIB or IV treated by EGFR tyrosine kinase inhibitors
- Demographic, diagnostic and medical data
- Stage (TNM, grade)
- EGFR mutation status
- Treatment History and medical out-come
- Treatment response to EGFR tyrosine kinase inhibitors treatment
LC-8
Non-Small Cell Lung Cancer (EGFR)
FFPE Blocks
Retrospective
More than 50 subjects
- Primary tumor or metastasis
- Progression on prior first-line therapy with different EGFR tyrosine kinase inhibitors
- Tissue must have been obtained after progression.
- Demographic, diagnostic and medical data
- Stage (TNM, grade)
- Treatment History
- Mutation data (point mutation in Exons)
LC-9
Non-Small Cell Lung Cancer (EGFR)
Plasma
Prospective
More than 300 subjects
2 groups:
- Stage III and IV NSCLC with mutated EGFR
- Stage III and IV NSCLC non-smokers women and/or Asians
- EDTA plasma aliquoted in 5 Eppendorf tubes
- Demographic, diagnostic and medical data
- Stage (TNM, grade)
- Treatment History and medical out-come
- Alcohol and smoking history
LC-10
Non-Small Cell Lung Carcinoma
FFPE Block and PBMC
Retrospective
More than 50 subjects
- FFPE block and PBMC collected at diagnosis, before start of any treatment
- Demographic, diagnostic and medical data
- Stage (TNM, grade)
- Treatment History and medical out-come
- If available, biomarker status: cMET, PI3K, EGFR, PTEN, ALK, ROS1, BRAF, HER2, NRAS…
LC-11
Non-Small Cell Lung Carcinoma
FFPE Blocks
Retrospective
More than 100 subjects
- FFPE surgery resected tissue blocks
- Any stage
- Patients newly diagnosed and prior to treatment
- Demographic, diagnostic and medical data
- Stage (TNM, grade)
- Treatment History
- 5 years medical follow-up
LC-12
Non-Small Cell Lung Carcinoma
Whole Blood
Retrospective
More than 100 subjects
- Stage IV NSCLC subjects
- Only chemotherapy naïve donors
- Blood sample collected directly into specific tubes and transported at room Temperature (16-25OC)
- Demographic, diagnostic and medical data
- Stage (TNM, grade)
- Treatment History and medical out-come
LC-13
Non-Small Cell Lung Cancer
Serum
Retrospective
More than 300 subjects
10 groups
- Stage I NSCLC adenocarcinoma, smokers and survived < 5 years from diagnosis
- Stage I NSCLC adenocarcinoma, smokers and survived > 5 years from diagnosis
- Stage I NSCLC adenocarcinoma, never-smokers and survived < 5 years from diagnosis
- Stage I NSCLC adenocarcinoma, never-smokers who survived > 5 years from diagnosis
- Stage II NSCLC adenocarcinoma, smokers and survived < 5 years from diagnosis
- Stage II NSCLC adenocarcinoma, smokers and survived > 5 years from diagnosis
- Mesothelioma
- IPF, bronchiectasis, asthma or pulmonary tuberculosis
- SCLC
- Healthy control subjects.
- Collection within 1 month of confirmed diagnosis and prior to start of any drug treatment or surgery
- Must not have had drug treatment associated to pulmonary disease in the 3 months prior to sample collection
- Must not have had surgery associate with pulmonary disease
- Demographic, diagnostic and medical data
- Stage (TNM, grade)
- Treatment History and medical out-come
- Smoking habits
LC-14
Non-Small Cell Lung Cancer (KRAS)
FFPE Blocks
Retrospective
More than 35 subjects
- Known KRAS codon 12 and 13 mutation status
- Any NSCLC subtype, any stage
- Demographic, diagnostic and medical data
- Stage (TNM, grade)
- Method used to detect KRAS mutation
LC-15
Small Cell Lung Carcinoma
FFPE Blocks
Retrospective
More than 180 subjects
- Any stage
- Demographic, diagnostic and medical data
- Stage (TNM, grade)
LC-16
Mesothelioma
FFPE Blocks
Retrospective
More than 180 subjects
- Samples collected over the past 4 years
- Age, gender
- Date of sample collection
- Stage
OC-1
Uveal Melanoma
FFPE Blocks
Retrospective
More than 15 subjects
- Diagnosed with Uveal Melanoma
- Age, Gender, Ethnicity
- Sample collection date
- Tumor location and size
- Pathological diagnosis
OC-2
Parotid Gland Cancer
FFPE Blocks
Retrospective
More than 15 subjects
- Advanced and metastatic
- Age, Gender, Ethnicity
- Medical history
- Tumor location and size
- Pathological diagnosis
OC-3
Thyroid Cancer
FFPE and Matched Frozen Tissue
Retrospective
More than 10 subjects
- 50% Medullary carcinoma and 50% parafollicular hyperplasia
- Diagnosed with thyroid cancer
- Age, Gender, Ethnicity
- Sample collection date
- Pathological diagnosis
- Medical history
OC-4
Fallopian Tube Cancer
FFPE Blocks
Retrospective
More than 40 subjects
- Stage IIIB or higher
- Age, Gender, Ethnicity
- TNM
- Medical history
- Pathology diagnosis
OC-5
Pheochromocytoma
Plasma and Matched Frozen Tissue or FFPE
Retrospective
More than 50 subjects
2 groups:
- 50% subjects with benign pheochromocytoma
- 50% subjects with malignant pheochromocytoma
- Pre-surgery plasma samples only
- Ischemia time < 1 hour for tissue
- Age, Gender, Ethnicity
- Sample collection date
- Clinical data
- Treatment history
OC-6
Head & Neck Cancer
FFPE
Retrospective
More than 40 subjects
6 groups:
- Tongue
- Larynx
- Nasopharynx
- Oropharynx
- Tonsil
- Hypopharynx
- Squamous Cell Carcinoma
- Age, Gender, Ethnicity
- TNM
- Clinical data
- Pathology diagnosis